• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外照射放疗与恩替诺特西雷夫:对DNA损伤修复的抑制及辐射介导病毒增加的机制

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

作者信息

Pokrovska Tzveta D, Jacobus Egon J, Puliyadi Rathi, Prevo Remko, Frost Sally, Dyer Arthur, Baugh Richard, Rodriguez-Berriguete Gonzalo, Fisher Kerry, Granata Giovanna, Herbert Katharine, Taverner William K, Champion Brian R, Higgins Geoff S, Seymour Len W, Lei-Rossmann Janet

机构信息

Anticancer Viruses and Cancer Vaccines Research Group, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Tumour Radiosensitivity Research Group, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

出版信息

Cancers (Basel). 2020 Mar 26;12(4):798. doi: 10.3390/cancers12040798.

DOI:10.3390/cancers12040798
PMID:32224979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7226394/
Abstract

Ionising radiation causes cell death through the induction of DNA damage, particularly double-stranded DNA (dsDNA) breaks. Evidence suggests that adenoviruses inhibit proteins involved in the DNA damage response (DDR) to prevent recognition of double-stranded viral DNA genomes as cellular dsDNA breaks. We hypothesise that combining adenovirus treatment with radiotherapy has the potential for enhancing tumour-specific cytotoxicity through inhibition of the DDR and augmentation of virus production. We show that EnAd, an Ad3/Ad11p chimeric oncolytic adenovirus currently being trialled in colorectal and other cancers, targets the DDR pathway at a number of junctures. Infection is associated with a decrease in irradiation-induced 53BP1 and Rad51 foci formation, and in total DNA ligase IV levels. We also demonstrate a radiation-associated increase in EnAd production in vitro and in a pilot in vivo experiment. Given the current limitations of in vitro techniques in assessing for synergy between these treatments, we adapted the plaque assay to allow monitoring of viral plaque size and growth and utilised the xCELLigence cell adhesion assay to measure cytotoxicity. Our study provides further evidence on the interaction between adenovirus and radiation in vitro and in vivo and suggests these have at least an additive, and possibly a synergistic, impact on cytotoxicity.

摘要

电离辐射通过诱导DNA损伤,特别是双链DNA(dsDNA)断裂,导致细胞死亡。有证据表明,腺病毒会抑制参与DNA损伤反应(DDR)的蛋白质,以防止双链病毒DNA基因组被识别为细胞dsDNA断裂。我们假设,将腺病毒治疗与放射疗法相结合,有可能通过抑制DDR和增加病毒产生来增强肿瘤特异性细胞毒性。我们发现,EnAd是一种目前正在结直肠癌和其他癌症中进行试验的Ad3/Ad11p嵌合溶瘤腺病毒,它在多个节点靶向DDR途径。感染与辐射诱导的53BP1和Rad51病灶形成减少以及总DNA连接酶IV水平降低有关。我们还在体外和一项体内初步实验中证明了辐射会使EnAd产生增加。鉴于目前体外技术在评估这些治疗之间协同作用方面的局限性,我们改进了噬斑测定法以监测病毒噬斑大小和生长情况,并利用xCELLigence细胞黏附测定法来测量细胞毒性。我们的研究为腺病毒与辐射在体外和体内的相互作用提供了进一步证据,并表明它们对细胞毒性至少具有相加作用,甚至可能具有协同作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/6a4dc81fbaa0/cancers-12-00798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/8d454d99c6d4/cancers-12-00798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/7240a0615eff/cancers-12-00798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/dbe3e577cc72/cancers-12-00798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/8e0645655ed8/cancers-12-00798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/cd82997258f1/cancers-12-00798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/6a4dc81fbaa0/cancers-12-00798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/8d454d99c6d4/cancers-12-00798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/7240a0615eff/cancers-12-00798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/dbe3e577cc72/cancers-12-00798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/8e0645655ed8/cancers-12-00798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/cd82997258f1/cancers-12-00798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caea/7226394/6a4dc81fbaa0/cancers-12-00798-g006.jpg

相似文献

1
External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.外照射放疗与恩替诺特西雷夫:对DNA损伤修复的抑制及辐射介导病毒增加的机制
Cancers (Basel). 2020 Mar 26;12(4):798. doi: 10.3390/cancers12040798.
2
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.人 CD46 的表达和鼠腺病毒 1 的转互补作用不能使 B 组溶瘤腺病毒在鼠癌细胞中进行有效的感染。
J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.
3
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.溶瘤腺病毒对Mre11的抑制作用与自噬相关,并构成其与电离辐射协同作用的基础。
Int J Cancer. 2009 Nov 15;125(10):2441-9. doi: 10.1002/ijc.24608.
4
A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.一种可检测抑制 DNA 损伤反应的 Epstein-Barr 病毒蛋白的筛选方法揭示了一种新型的组蛋白结合蛋白。
J Virol. 2018 Jun 29;92(14). doi: 10.1128/JVI.00262-18. Print 2018 Jul 15.
5
Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.溶瘤腺病毒与放疗联合——放射增敏未来的一种模式
Front Oncol. 2017 Jul 24;7:153. doi: 10.3389/fonc.2017.00153. eCollection 2017.
6
The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.腺病毒E4orf4蛋白为抑制DNA损伤反应提供了一种新机制。
PLoS Pathog. 2016 Feb 11;12(2):e1005420. doi: 10.1371/journal.ppat.1005420. eCollection 2016 Feb.
7
Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.端粒酶依赖性溶瘤腺病毒通过抑制 DNA 修复机制使人类癌细胞对电离辐射敏感。
Cancer Res. 2010 Nov 15;70(22):9339-48. doi: 10.1158/0008-5472.CAN-10-2333. Epub 2010 Nov 2.
8
Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.奥拉帕利和电离辐射触发协同的 DNA 损伤修复反应,而 VRK1 染色质激酶耗竭会损害这种反应。
J Exp Clin Cancer Res. 2019 May 17;38(1):203. doi: 10.1186/s13046-019-1204-1.
9
Adenovirus Core Protein VII Downregulates the DNA Damage Response on the Host Genome.腺病毒核心蛋白VII下调宿主基因组上的DNA损伤反应。
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.01089-17. Print 2017 Oct 15.
10
USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination.USP14 通过靶向 RNF168 依赖性泛素化调节 DNA 损伤修复。
Autophagy. 2018;14(11):1976-1990. doi: 10.1080/15548627.2018.1496877. Epub 2018 Aug 10.

引用本文的文献

1
Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms.溶瘤腺病毒与免疫检查点抑制剂的协同作用:转变癌症免疫治疗模式
Front Immunol. 2025 Jul 8;16:1610858. doi: 10.3389/fimmu.2025.1610858. eCollection 2025.
2
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments.增强癌症治疗效果:溶瘤病毒疗法与多种治疗方法的整合
Cancer Cell Int. 2024 Jul 11;24(1):242. doi: 10.1186/s12935-024-03424-z.
3
The Future of Interventions for Stage IV Colorectal Cancers.

本文引用的文献

1
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.双价和三价 T 细胞衔接器在癌症患者样本中耗尽肿瘤相关巨噬细胞。
J Immunother Cancer. 2019 Nov 21;7(1):320. doi: 10.1186/s40425-019-0807-6.
2
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).一项评估腺病毒 Enadenotucirev(一种溶瘤病毒)治疗上皮性实体瘤患者的 I 期剂量递增研究(EVOLVE)。
J Immunother Cancer. 2019 Jan 28;7(1):20. doi: 10.1186/s40425-019-0510-7.
3
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
IV期结直肠癌干预措施的未来
Clin Colon Rectal Surg. 2023 Feb 7;37(2):114-121. doi: 10.1055/s-0043-1761624. eCollection 2024 Mar.
4
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.结直肠癌的当前及新出现的治疗方法:全面综述
World J Gastrointest Surg. 2023 Apr 27;15(4):495-519. doi: 10.4240/wjgs.v15.i4.495.
5
Current landscape and perspective of oncolytic viruses and their combination therapies.溶瘤病毒及其联合疗法的当前现状与前景。
Transl Oncol. 2022 Nov;25:101530. doi: 10.1016/j.tranon.2022.101530. Epub 2022 Sep 9.
6
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.三型嵌合溶瘤腺病毒针对实体瘤发挥多种协同作用机制。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004691.
7
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.DNA损伤反应中的蛋白质:调控、功能障碍与抗癌策略
Cancers (Basel). 2021 Jul 29;13(15):3819. doi: 10.3390/cancers13153819.
8
Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.溶瘤病毒治疗的发展演变:临床实践中的挑战与展望。
JCO Precis Oncol. 2021 Feb 24;5. doi: 10.1200/PO.20.00395. eCollection 2021.
9
Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.免疫溶瘤病毒:结直肠癌治疗的新选择。
Mol Diagn Ther. 2021 May;25(3):301-313. doi: 10.1007/s40291-021-00517-7. Epub 2021 Mar 12.
10
The Role of Adenovirus in Cancer Therapy.腺病毒在癌症治疗中的作用。
Cancers (Basel). 2020 Oct 26;12(11):3121. doi: 10.3390/cancers12113121.
表达 T 细胞衔接器的溶瘤病毒可同时靶向肿瘤和免疫抑制性基质细胞。
Cancer Res. 2018 Dec 15;78(24):6852-6865. doi: 10.1158/0008-5472.CAN-18-1750. Epub 2018 Nov 18.
4
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.人 CD46 的表达和鼠腺病毒 1 的转互补作用不能使 B 组溶瘤腺病毒在鼠癌细胞中进行有效的感染。
J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.
5
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.RAD51 焦点作为同源重组修复的功能生物标志物和种系 BRCA 突变乳腺癌中 PARP 抑制剂耐药性。
Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
6
Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.免疫疗法与放射疗法联合用于癌症治疗:当前挑战与未来方向
Front Pharmacol. 2018 Mar 5;9:185. doi: 10.3389/fphar.2018.00185. eCollection 2018.
7
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.嵌合腺病毒 enadenotucirev 静脉给药的 1 期研究,该研究在接受原发肿瘤切除术的患者中进行。
J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.
8
Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.溶瘤腺病毒与放疗联合——放射增敏未来的一种模式
Front Oncol. 2017 Jul 24;7:153. doi: 10.3389/fonc.2017.00153. eCollection 2017.
9
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.表达双特异性抗体的溶瘤腺病毒靶向癌症活检中的T细胞细胞毒性。
EMBO Mol Med. 2017 Aug;9(8):1067-1087. doi: 10.15252/emmm.201707567.
10
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.开发一种通用的溶瘤病毒平台,用于治疗性转基因在肿瘤内局部表达。
PLoS One. 2017 May 18;12(5):e0177810. doi: 10.1371/journal.pone.0177810. eCollection 2017.